Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOCHVE)

Drug Name

SL-401 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 1/2	[1]
Blastic plasmacytoid dendritic cell neoplasm	2A60.5	Phase 1/2	[1]
Multiple myeloma	2A83	Phase 1/2	[2]
Myeloproliferative neoplasm	2A20	Phase 1/2	[2]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin 3 receptor (CSF2RB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Leridistim	DM6DL5K	Immune System disease	4A01-4B41	Phase 2	[4]
TPI ASM8	DMAWLVB	Asthma	CA23	Phase 2	[5]
DT388IL-3	DMRXQCL	Acute myeloid leukaemia	2A60	Phase 1/2	[6]
CSL-362	DMO97RV	Acute myeloid leukaemia	2A60	Phase 1	[7]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT02113982) SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92.
4	Leridistim, a chimeric dual G-CSF and IL-3 receptor agonist, enhances multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression: effect of schedule, dose, and route of administration. Stem Cells. 2001;19(6):522-33.
5	Target mRNA inhibition by oligonucleotide drugs in man. Nucleic Acids Res.2012 Nov;40(21):10585-95.
6	Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunol Immunother. 2005 Aug;54(8):799-806.
7	Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014 Feb 20;123(8):1218-28.